The Parker Institute for Cancer Immunotherapy and its six affiliated research institutions have agreed to streamline the review process for faster approval of multicenter clinical trials. This approach is designed to get clinical trials off the ground in weeks, rather than months, saving both time and resources.
You Might Also Like...
Research initiative aims to better understand link between immunotherapy, type 1 diabetes
HemOnc Today | August 7, 2019